Neuroscience
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release.
- Alzheimer: Clinical Trials Day At The Aaic2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015. - Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years - Biomarker Results from Phase 3 Gantenerumab (Roche) Trial - New Data from Aducanumab (Biogen) Phase 1b...
- Alzheimer's Disease: Gammagard Fails
From the company press release: Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease DEERFIELD, Ill., May 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of...
- Alzheimer's Disease: A Wrap For Bap
Trials for Alzheimer’s Drug Halted After Poor Results By KATIE THOMAS The New York Times 06 August 2012 Read full article ---Corporate Press Release: Read the releaseCommentary from the In The Pipeline blog: In The PipelineCommentary from Pharmalot:...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Business World: Neurochem's Alzhemed And Alzheimer Disease
Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed(TM) Milestone on Schedule Tuesday July 5, 8:31 am ET LAVAL, QC, July 5 /PRNewswire-FirstCall/ - Neurochem Inc. ... announced today the completion of recruitment...
Neuroscience
Alzheimer's Disease: Negative Bapineuzumab Findings in Phase III Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release.
From FierceBiotech:
UPDATED: Pfizer, J&J Alzheimer's drug bapineuzumab flunks out in big PhIII
July 23, 2012
By John Carroll
Read the full article
Examine media reports this week for these results and accompanying analysis and commentary. Those who have been following this clinical-trial program should examine the corporate press release for additional details about the other three Phase III trials in this program (which were not part of today's results).
- Alzheimer: Clinical Trials Day At The Aaic2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015. - Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years - Biomarker Results from Phase 3 Gantenerumab (Roche) Trial - New Data from Aducanumab (Biogen) Phase 1b...
- Alzheimer's Disease: Gammagard Fails
From the company press release: Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease DEERFIELD, Ill., May 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of...
- Alzheimer's Disease: A Wrap For Bap
Trials for Alzheimer’s Drug Halted After Poor Results By KATIE THOMAS The New York Times 06 August 2012 Read full article ---Corporate Press Release: Read the releaseCommentary from the In The Pipeline blog: In The PipelineCommentary from Pharmalot:...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Business World: Neurochem's Alzhemed And Alzheimer Disease
Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed(TM) Milestone on Schedule Tuesday July 5, 8:31 am ET LAVAL, QC, July 5 /PRNewswire-FirstCall/ - Neurochem Inc. ... announced today the completion of recruitment...